Viridian Therapeutics Inc
$ 29.49
1.90%
26 Feb - close price
- Market Cap 2,762,092,000 USD
- Current Price $ 29.49
- High / Low $ 29.58 / 26.31
- Stock P/E N/A
- Book Value 3.82
- EPS -3.03
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.50 %
- 52 Week High 34.29
- 52 Week Low 9.90
About
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses. The company is headquartered in Boulder, Colorado.
Analyst Target Price
$42.06
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-25 | 2024-11-11 | 2024-08-08 | 2024-05-08 | 2024-02-27 | 2023-11-13 | 2023-08-08 | 2023-05-09 | 2023-03-08 |
| Reported EPS | -0.34 | -1 | -0.869 | -0.81 | -1.1546 | -1.02 | -0.79 | -1.35 | -1.09 | -1.27 | -1.61 | -1.13 |
| Estimated EPS | -0.9532 | -1 | -1.1 | -1.0442 | -1.06 | -0.89 | -1.1 | -1 | -1.27 | -1.29 | -1.02 | -0.73 |
| Surprise | 0.6132 | 0 | 0.231 | 0.2342 | -0.0946 | -0.13 | 0.31 | -0.35 | 0.18 | 0.02 | -0.59 | -0.4 |
| Surprise Percentage | 64.3307% | 0% | 21% | 22.4287% | -8.9245% | -14.6067% | 28.1818% | -35% | 14.1732% | 1.5504% | -57.8431% | -54.7945% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.9 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VRDN
2026-02-23 19:12:35
Commodore Capital has fully divested its 3,200,000-share stake in Viridian Therapeutics (NASDAQ:VRDN), a transaction valued at an estimated $69.06 million. This complete sell-off, which occurred despite a 75% increase in Viridian's stock over the past year, reduces Viridian's weighting in Commodore Capital's portfolio from 3.4% to zero. The move suggests the fund is prioritizing risk calibration ahead of Viridian's catalyst-heavy year, which includes an FDA PDUFA date for veligrotug and topline Phase 3 data for elegrobart.
2026-02-23 16:35:34
Commodore Capital has fully divested its 3.2 million share position in Viridian Therapeutics, a transaction valued at an estimated $69.06 million. This move comes despite Viridian Therapeutics' stock increasing by 75% over the past year and the company having significant potential catalysts, including an FDA PDUFA date and upcoming Phase 3 data. The decision by Commodore Capital appears to be a matter of risk calibration or valuation discipline after the stock's strong performance.
2026-02-21 12:36:03
Viridian Therapeutics has finished enrolling patients for its Phase III THRIVE-2 clinical trial of VRDN-001, a treatment for chronic thyroid eye disease (TED), with 188 patients enrolled globally. The company expects to release topline data for THRIVE-2 by the end of the year, following the anticipated September readout for its THRIVE trial for active TED. Additionally, Viridian plans to initiate two Phase III trials for a subcutaneous version of its anti-IGF-1R antibody, VRDN-003, in August.
2026-02-20 19:39:55
Viridian is poised for significant activity in 2026 with an anticipated FDA approval for its first drug and multiple clinical trial readouts. The company is focusing on developing treatments for Thyroid Eye Disease (TED) and has other FcRn programs expected to yield Phase I data. This strategic outlook positions Viridian for growth in the biopharmaceutical sector.
2026-02-20 19:26:07
Viridian is preparing for an important year in 2026, with expectations of FDA approval for its first drug and multiple clinical trial readouts, including two FcRn programs. The company aims to launch a drug for Thyroid Eye Disease (TED) and has a fast follower in the same therapeutic area, positioning itself strongly in the ophthalmology market. This comes as a rival, Argenx, experienced a setback with its Vvygart drug in TED.
2026-02-19 17:23:42
Viridian Therapeutics (NASDAQ:VRDN) is expected to report its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting a loss of ($0.88) per share. The company currently holds a "Moderate Buy" consensus rating with an average price target of $42.64. Recent insider trading activity includes a sale of shares by Jennifer Tousignant, and various institutional investors have adjusted their holdings in VRDN.
